Daniel R. Gomez, MD

Articles by Daniel R. Gomez, MD

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 28th 2023

Conclusion of the discussion and award presentation.

Optimal Approach for PD-L1 >50%

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Treatment for Borderline Resectable Patients With NSCLC

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion on the treatment for borderline resectable patients with NSCLC.

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Introduction of the Debate Between Jets v. Giants

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

An outline of the debate, the speakers, and the basic guidelines to support the program.

Achieving Value in Cancer Care

ByDaniel R. Gomez, MD

March 29th 2017

This video explores the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level while maintaining optimal care for cancer patients.

Daniel R. Gomez, MD

Articles by Daniel R. Gomez, MD

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

Optimal Approach for PD-L1 >50%

Treatment for Borderline Resectable Patients With NSCLC

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

Introduction of the Debate Between Jets v. Giants

Achieving Value in Cancer Care

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment